Showing results (91-100 of 195) with videos related to
Sort By:
Pageof 20
Trials|August 8, 2014
A pilot randomised controlled trial of a Telehealth intervention in patients with chronic obstructive pulmonary disease: challenges of clinician-led data collectionClaire L Bentley, Gail A Mountain, Jill Thompson, et al.Health and Social Care Delivery Research|October 14, 2023
Explanation of context, mechanisms and outcomes in adult community mental health crisis care: the MH-CREST realist evidence synthesisNicola Clibbens, John Baker, Andrew Booth, et al.Cancer Research|January 11, 2007
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapyUma Thanarajasingam, Laura Sanz, Rosa Diaz, et al.Cancer Research|March 17, 2007
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virusRosa Maria Diaz, Feorillo Galivo, Timothy Kottke, et al.The American Naturalist|June 10, 2016
Interspecific Functional Convergence and Divergence and Intraspecific Negative Density Dependence Underlie the Seed-to-Seedling Transition in Tropical TreesMaria Natalia Umaña, Jimena Forero-Montaña, Robert Muscarella, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2006
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomasLuis Sanchez-Perez, Timothy Kottke, Gregory A Daniels, et al.Nature Biotechnology|June 10, 2003
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilizationAtique Ahmed, Jill Thompson, Lisa Emiliusen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.Cancer Research|May 21, 2010
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancerPhonphimon Wongthida, Rosa Maria Diaz, Feorillo Galivo, et al.Pageof 20